Alumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock Up

Alumis reported new Phase 3 findings from the ONWARD1, ONWARD2 and ONWARD3 studies, saying investigational envudeucitinib rapidly and durably improved scalp psoriasis, itching and quality of life in patients with moderate-to-severe plaque psoriasis. The provided article excerpt gives no numerical effect sizes or further trial details.